Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-07-14Clinical Trial Update: High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 [Phase 3]
This entry documents a Phase 3 trial evaluating high-dose ribavirin for chronic hepatitis C genotype 1 or 4, which has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-07-10Clinical Trial Update: To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet [Phase 1]
Completed Phase 1 pharmacokinetic study evaluating the impact of renal impairment on blood levels of a fixed-dose combination tablet contain…
-
CLINICAL_TRIALS trial_result · 2014-07-09Clinical Trial Update: Pirfenidone, an Antifibrotic and Antiinflammatory Drug [Phase 2]
Phase 2 trial of pirfenidone, an antifibrotic and anti-inflammatory drug, has completed evaluating its effects in fibrosis and chronic hepat…
-
CLINICAL_TRIALS trial_result · 2014-07-08Clinical Trial Update: The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection [Phase 2]
Phase 2 trial evaluating adding TCM-700C to standard treatment for genotype 1 chronic hepatitis C. Results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-07-04Clinical Trial Update: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C [Phase 2]
Phase 2 study evaluating VX-222 in combination with telaprevir and ribavirin for genotype 1a chronic hepatitis C in treatment-naive patients…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2014-06-27European Medicines Agency recommends approval of Daklinza in chronic hepatitis C
The European Medicines Agency recommends approval of Daklinza for use in chronic hepatitis C, indicating regulatory endorsement for its indi…
-
CLINICAL_TRIALS trial_result · 2014-06-26Clinical Trial Update: Absolute Bioavailability of BMS-791325 [Phase 1]
Phase 1 trial reporting the absolute bioavailability of the investigational hepatitis C drug BMS-791325.
-
CLINICAL_TRIALS trial_result · 2014-06-19Clinical Trial Update: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV [Phase 2]
Phase 2 clinical trial update evaluating safety, tolerability, pharmacokinetics, and activity of GS-9450 in subjects with chronic hepatitis …
-
CLINICAL_TRIALS trial_result · 2014-06-18Clinical Trial Update: Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis [Phase 2]
Phase 2 trial assessing the antifibrotic activity of Fuzheng Huayu in patients with chronic hepatitis C and hepatic fibrosis; study complete…
-
CLINICAL_TRIALS trial_result · 2014-06-17Clinical Trial Update: Drug Interaction & Methadone & Buprenorphine [Phase 1]
Phase 1 trial evaluating potential interactions between a hepatitis C therapy and methadone or buprenorphine, with the study now completed.
-
CLINICAL_TRIALS trial_result · 2014-06-17Clinical Trial Update: Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects [Phase 1]
This Phase 1 study assesses potential drug-drug interactions when the three-drug hepatitis C antiviral combination (daclatasvir/asunaprevir/…
-
CLINICAL_TRIALS research · 2014-06-17Clinical Trial Update: Clinical Investigation of Erlotinib as an HCV Entry Inhibitor [Phase 1, Phase 2]
A clinical trial update on the investigation of Erlotinib as an entry inhibitor for hepatitis C, spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2014-06-16Clinical Trial Update: A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment [Phase 2]
Phase 2 study of TMC435 (telaprevir) with pegylated interferon alfa-2a and ribavirin in genotype 1 hepatitis C patients who never received t…
-
CLINICAL_TRIALS trial_result · 2014-06-16Clinical Trial Update: Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections [Phase 4]
A Phase 4 trial evaluating pioglitazone for fatty liver disease in patients with HIV and hepatitis C was terminated, with results posted in …
-
CLINICAL_TRIALS trial_result · 2014-06-13Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants [Phase 3]
Phase 3 trial results for TMC435 in treatment-naive genotype 1 hepatitis C patients, assessing efficacy, safety, and tolerability, with resu…
-
CLINICAL_TRIALS trial_result · 2014-06-12Clinical Trial Update: Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
This clinical trial update reports patient-reported quality of life outcomes during treatment for chronic hepatitis C genotype 1, with resul…
-
CLINICAL_TRIALS trial_result · 2014-06-11Clinical Trial Update: Boceprevir Treatment in Liver Pre-transplant HCV Patients [Phase 3]
Phase 3 trial update evaluating boceprevir for hepatitis C in liver transplant candidates.
-
CLINICAL_TRIALS trial_result · 2014-06-04Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients [Phase 3]
Phase 3 trial evaluating the efficacy, safety, and tolerability of Simeprevir (TMC435) in treatment-naive genotype 1 Hepatitis C patients; r…
-
CLINICAL_TRIALS trial_result · 2014-06-04Clinical Trial Update: Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR [Phase 4]
Phase 4 clinical trial update evaluating peginterferon alfa-2a plus ribavirin for genotype 2 chronic hepatitis C, focusing on treatment dura…
-
CLINICAL_TRIALS trial_result · 2014-06-04Clinical Trial Update: VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection [Phase 3]
A Phase 3 trial comparing twice-daily versus every-8-hours dosing of telaprevir in treatment-naive genotype 1 chronic hepatitis C, with resu…
-
CLINICAL_TRIALS trial_result · 2014-06-03Clinical Trial Update: Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection [Phase 2]
A Phase 2 trial evaluated whether adding GI-5005 to pegylated interferon plus ribavirin improves outcomes versus standard of care in genotyp…
-
CLINICAL_TRIALS trial_result · 2014-05-30Clinical Trial Update: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir [Phase 4]
Phase 4 study update examining HCV evolution in HIV/HCV coinfected patients (genotype 1) treated with Fosamprenavir. The trial status is com…
-
CLINICAL_TRIALS trial_result · 2014-05-29Clinical Trial Update: The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function [Phase 2, Phase 3]
The study evaluates the Chinese herbal formula KSY for improving liver function in hepatitis C carriers, conducted in Phase 2 and Phase 3, a…
-
CLINICAL_TRIALS trial_result · 2014-05-29Clinical Trial Update: A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. [Phase 4]
This Phase 4 pilot trial assesses the efficacy and safety of folic acid and/or a Vitamin B complex in Hepatitis C patients treated with pegy…
-
CLINICAL_TRIALS trial_result · 2014-05-26Clinical Trial Update: Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 [Phase 2]
Phase 2 study evaluating Sofosbuvir with Pegylated Interferon and Ribavirin in chronic hepatitis C patients across genotypes 1, 4, 5, and 6 …